세계의 인플루엔자 치료 시장 보고서(2025년)

Influenza Treatment Global Market Report 2025

US $ 4,490 ￦ 6,319,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,134,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,949,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

인플루엔자 치료 시장 규모는 향후 몇 년 동안 안정적인 성장을 보일 것으로 예상되며, 2029년에는 연평균 성장률(CAGR) 4.3%로 81억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 새로운 항바이러스제 및 치료법 도입, 백신 접종 프로그램 확대, 의료 인프라의 지속적인 확장 및 개선, 노인 인구 증가, 새로운 치료법 개발 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 범용 백신 개발의 진전, 백신 전달 시스템의 혁신, AI와 빅데이터의 통합, 맞춤형 의료의 발전, 제약사 간 협력 관계 강화 등을 들 수 있습니다.

전염성 호흡기질환의 발병률 증가는 인플루엔자 치료 시장을 견인할 것으로 예상됩니다. 전염성 호흡기질환에는 인플루엔자, 홍역, 호흡기세포융합바이러스(RSV) 감염과 같은 감염성 질환이 포함되며, 감염자 또는 감염자의 체액, 오염된 표면, 물체와의 접촉을 통해 전파됩니다. 전염성 호흡기질환의 증가를 촉진하는 요인으로는 인구 밀도의 증가, 불충분한 의료 인프라, 항생제 오남용, 해외여행의 촉진 등을 들 수 있습니다. 독감 치료에서는 독감, COVID-19, 기타 호흡기 바이러스 등 다양한 전염성 호흡기질환을 관리하기 위해 항바이러스제 및 예방접종이 사용되고 있습니다. 예를 들어, 미국 질병통제예방센터(CDC)에 따르면, 2023년 9월 RSV(호흡기세포융합바이러스) 관련 입원율은 2023년 8월 5일로 끝나는 주에 10만 명당 2명에서 2023년 8월 19일로 끝나는 주에 10만 명당 7명으로 증가하였다고 합니다.만 명당 7명으로 증가했습니다. 따라서 전염성 호흡기질환의 유병률 증가는 인플루엔자 치료 시장의 성장을 촉진하고 있습니다.

인플루엔자 치료 시장의 선두주자들은 환자의 순응도를 높이고, 치료 결과를 개선하며, 시장 점유율을 확대하기 위해 독감 치료용 1회용 경구제와 같은 혁신적인 솔루션을 도입하여 제품의 폭을 넓히는 데 주력하고 있습니다. 1회 경구용 약물은 1회 경구 투여로 독감에 대응할 수 있도록 제형화된 약물로, 치료 요법을 간소화할 수 있습니다. 예를 들어, 2022년 8월 미국 생명공학 기업 젠젠텍(Genentech)은 미국 식품의약국(FDA)의 승인을 받은 Xofluza(Baloxavir Marboxil)를 통해 48시간 이내에 증상이 나타난 5세 이상 12세 미만 소아 및 다른 호흡기 바이러스 합병증 없이 급성 독감을 관리할 수 있는 편리하고 효과적인 솔루션을 제공하는 유일한 1회 경구용 치료제입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 인플루엔자 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 인플루엔자 치료 시장 : 성장률 분석
• 세계의 인플루엔자 치료 시장 실적 : 규모와 성장, 2019-2024
• 세계의 인플루엔자 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 인플루엔자 치료 전체 시장(TAM)

제6장 시장 세분화

• 세계의 인플루엔자 치료 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 페라미비르
• 자나미비르
• 인산 오셀타미비르
• 발록사비르 마르복실
• 기타 제품
• 세계의 인플루엔자 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 기타 투여 경로
• 세계의 인플루엔자 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 소매 약국
• 병원 약국
• 기타 유통 채널
• 세계의 인플루엔자 치료 시장, 페라미비르 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 정맥내 페라미비르
• 페라미비르 주사제
• 세계의 인플루엔자 치료 시장, 자나미비르 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 흡입 자나미비르
• 자나미비르 디스칼러
• 세계의 인플루엔자 치료 시장, 인산 오셀타미비르 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 오셀타미비르 캡슐
• 오셀타미비르 경구 현탁액
• 세계의 인플루엔자 치료 시장, 발록사비르 마르복실 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 발록사비르 정제
• 경구 현탁용 발록사비르 과립제
• 세계의 인플루엔자 치료 시장, 기타 제품 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 리만타진
• 아만타진

제7장 지역별·국가별 분석

• 세계의 인플루엔자 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 인플루엔자 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 인플루엔자 치료 시장 : 경쟁 구도
• 인플루엔자 치료 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Fujifilm Holdings Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company Limited.
• Chugai Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Limited
• Cipla Ltd

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 인플루엔자 치료 시장 2029 : 새로운 기회를 제공하는 국가
• 인플루엔자 치료 시장 2029 : 새로운 기회를 제공하는 부문
• 인플루엔자 치료 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Influenza treatment involves medical measures intended to manage and relieve symptoms, shorten the duration of illness, and prevent complications linked to influenza virus infections. It includes antiviral drugs and supportive care aimed at alleviating flu symptoms, shortening the illness duration, and averting severe complications.

The primary products employed for treating influenza include peramivir, zanamivir, oseltamivir phosphate, baloxavir marboxil, and others. Peramivir is an antiviral drug utilized for influenza treatment. These medications can be administered via various routes, including orally and others, and are available through different distribution channels, such as retail pharmacies, hospital pharmacies, and others.

The influenza treatment market research report is one of a series of new reports from The Business Research Company that provides influenza treatment market statistics, including influenza treatment industry global market size, regional shares, competitors with a influenza treatment market share, detailed influenza treatment market segments, market trends and opportunities, and any further data you may need to thrive in the influenza treatment industry. This influenza treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza treatment market size has grown steadily in recent years. It will grow from $6.6 billion in 2024 to $6.9 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to a growth in number of annual influenza cases, increased government funding for influenza research and preparedness programs, public awareness campaigns promoting vaccination, the establishment of global influenza surveillance systems, and growth in healthcare facilities.

The influenza treatment market size is expected to see steady growth in the next few years. It will grow to $8.16 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to the introduction of new antiviral drugs and treatment modalities, expanding vaccination programs, continued expansion and improvement of healthcare infrastructure, increasing elderly population, and development of new treatments. Major trends in the forecast period include progress toward developing universal vaccines, innovations in vaccine delivery systems, integration of AI and big data, advances in personalized medicine, and increased collaborations between pharmaceutical companies.

The rising incidence of contagious respiratory illnesses is anticipated to drive the influenza treatment market forward. Contagious respiratory illnesses encompass infectious diseases such as influenza, measles, or respiratory syncytial virus (RSV) infections, which spread through contact with infected individuals or their bodily fluids, contaminated surfaces, or objects. Factors fueling the increase in contagious respiratory illnesses include higher population densities, inadequate healthcare infrastructure, misuse of antibiotics, and facilitated international travel. Influenza treatment involves the use of antiviral drugs and vaccinations to manage various contagious respiratory illnesses such as flu, COVID-19, and other respiratory viruses. For example, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the hospitalization rate associated with RSV (Respiratory Syncytial Virus) rose from 2 hospitalizations per 100,000 individuals during the week ending August 5, 2023, to 7 hospitalizations per 100,000 individuals by the week ending on August 19, 2023. Hence, the increased prevalence of contagious respiratory illnesses is propelling the growth of the influenza treatment market.

Prominent companies in the influenza treatment market are concentrating on broadening their product range by introducing innovative solutions, such as single-dose oral medication for influenza treatment, with the aim of enhancing patient adherence, improving treatment outcomes, and securing a larger market share. A single-dose oral medication is a drug formulated to address influenza (flu) with just one oral dose, simplifying the treatment regimen. For example, in August 2022, Genentech Inc., a US-based biotechnology company, revealed the U.S. Food and Drug Administration (FDA) approval for Xofluza (Baloxavir Marboxil). Xofluza stands as the premier and sole single-dose oral medication, providing a convenient and effective solution for managing acute uncomplicated influenza in children aged five to less than 12 years who have exhibited symptoms for no more than 48 hours, as well as other respiratory viruses.

In June 2022, Pfizer Inc., a pharmaceutical company headquartered in the United States, purchased ReViral for an undisclosed sum. This acquisition is aimed at broadening Pfizer's product portfolio by incorporating one of the therapeutic candidates, Sisunatovir, which is an orally administered inhibitor designed to specifically impede the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral is a biotechnology company based in the United Kingdom, known for its development and provision of innovative therapies for viral diseases.

Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd, Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

North America was the largest region in the influenza treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the influenza treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The influenza treatment market consists of sales of ibuprofen, dextromethorphan, acetaminophen, and nasal sprays. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on influenza treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The influenza treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Peramivir; Zanamivir; Oseltamivir Phosphate; Baloxavir Marboxil; Other Products
• 2) By Route Of Administration: Oral; Other Routes Of Administration
• 3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Other Distribution Channels
• Subsegments:
• 1) By Peramivir: Intravenous Peramivir; Peramivir Injection
• 2) By Zanamivir: Inhaled Zanamivir; Zanamivir Diskhaler
• 3) By Oseltamivir Phosphate: Oseltamivir Capsules; Oseltamivir Oral Suspension
• 4) By Baloxavir Marboxil: Baloxavir Tablets; Baloxavir Granules For Oral Suspension
• 5) Other Products: Rimantadine; Amantadine
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Influenza Treatment Market Characteristics

3. Influenza Treatment Market Trends And Strategies

4. Influenza Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Influenza Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Influenza Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Influenza Treatment Market Growth Rate Analysis
• 5.4. Global Influenza Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Influenza Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Influenza Treatment Total Addressable Market (TAM)

6. Influenza Treatment Market Segmentation

• 6.1. Global Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peramivir
• Zanamivir
• Oseltamivir Phosphate
• Baloxavir Marboxil
• Other Products
• 6.2. Global Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Other Routes Of Administration
• 6.3. Global Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Hospital Pharmacy
• Other Distribution Channels
• 6.4. Global Influenza Treatment Market, Sub-Segmentation Of Peramivir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Peramivir
• Peramivir Injection
• 6.5. Global Influenza Treatment Market, Sub-Segmentation Of Zanamivir, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Zanamivir
• Zanamivir Diskhaler
• 6.6. Global Influenza Treatment Market, Sub-Segmentation Of Oseltamivir Phosphate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oseltamivir Capsules
• Oseltamivir Oral Suspension
• 6.7. Global Influenza Treatment Market, Sub-Segmentation Of Baloxavir Marboxil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baloxavir Tablets
• Baloxavir Granules For Oral Suspension
• 6.8. Global Influenza Treatment Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rimantadine
• Amantadine

7. Influenza Treatment Market Regional And Country Analysis

• 7.1. Global Influenza Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Influenza Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Influenza Treatment Market

• 8.1. Asia-Pacific Influenza Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Influenza Treatment Market

• 9.1. China Influenza Treatment Market Overview
• 9.2. China Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Influenza Treatment Market

• 10.1. India Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Influenza Treatment Market

• 11.1. Japan Influenza Treatment Market Overview
• 11.2. Japan Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Influenza Treatment Market

• 12.1. Australia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Influenza Treatment Market

• 13.1. Indonesia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Influenza Treatment Market

• 14.1. South Korea Influenza Treatment Market Overview
• 14.2. South Korea Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Influenza Treatment Market

• 15.1. Western Europe Influenza Treatment Market Overview
• 15.2. Western Europe Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Influenza Treatment Market

• 16.1. UK Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Influenza Treatment Market

• 17.1. Germany Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Influenza Treatment Market

• 18.1. France Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Influenza Treatment Market

• 19.1. Italy Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Influenza Treatment Market

• 20.1. Spain Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Influenza Treatment Market

• 21.1. Eastern Europe Influenza Treatment Market Overview
• 21.2. Eastern Europe Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Influenza Treatment Market

• 22.1. Russia Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Influenza Treatment Market

• 23.1. North America Influenza Treatment Market Overview
• 23.2. North America Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Influenza Treatment Market

• 24.1. USA Influenza Treatment Market Overview
• 24.2. USA Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Influenza Treatment Market

• 25.1. Canada Influenza Treatment Market Overview
• 25.2. Canada Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Influenza Treatment Market

• 26.1. South America Influenza Treatment Market Overview
• 26.2. South America Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Influenza Treatment Market

• 27.1. Brazil Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Influenza Treatment Market

• 28.1. Middle East Influenza Treatment Market Overview
• 28.2. Middle East Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Influenza Treatment Market

• 29.1. Africa Influenza Treatment Market Overview
• 29.2. Africa Influenza Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Influenza Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Influenza Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Influenza Treatment Market Competitive Landscape And Company Profiles

• 30.1. Influenza Treatment Market Competitive Landscape
• 30.2. Influenza Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Influenza Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc
• 31.4. Takeda Pharmaceutical Company
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Gilead Sciences Inc.
• 31.7. Fujifilm Holdings Corporation
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Janssen Pharmaceuticals Inc.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Daiichi Sankyo Company Limited.
• 31.13. Chugai Pharmaceutical Co. Ltd.
• 31.14. Sun Pharmaceutical Industries Limited
• 31.15. Cipla Ltd

32. Global Influenza Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Influenza Treatment Market

34. Recent Developments In The Influenza Treatment Market

35. Influenza Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Influenza Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Influenza Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Influenza Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료